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Selection of the right drug for the right patient is a promising approach to increase
clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment
of in vivo biodistribution and tumor targeting of mAbs to predict toxicity and efficacy
is expected to guide individualized treatment and drug development. Molecular
imaging with positron emission tomography (PET) using zirconium-89 (89Zr)-labeled
monoclonal antibodies also known as 89Zr-immuno-PET, visualizes and quantifies
uptake of radiolabeled mAbs. This technique provides a potential imaging biomarker
to assess target expression, as well as tumor targeting of mAbs. In this review we
summarize results from initial clinical trials with 89Zr-immuno-PET in oncology and
discuss technical aspects of trial design. In clinical trials with 89Zr-immuno-PET two
requirements should be met for each 89Zr-labeled mAb to realize its full potential.
One requirement is that the biodistribution of the 89Zr-labeled mAb (imaging dose)
reflects the biodistribution of the drug during treatment (therapeutic dose). Another
requirement is that tumor uptake of 89Zr-mAb on PET is primarily driven by specific,
antigen-mediated, tumor targeting. Initial trials have contributed toward the development
of 89Zr-immuno-PET as an imaging biomarker by showing correlation between
uptake of 89Zr-labeled mAbs on PET and target expression levels in biopsies.
These results indicate that 89Zr-immuno-PET reflects specific, antigen-mediated
binding. 89Zr-immuno-PET was shown to predict toxicity of RIT, but thus far results
indicating that toxicity of mAbs or mAb-drug conjugate treatment can be predicted
are lacking. So far, one study has shown that molecular imaging combined with early
response assessment is able to predict response to treatment with the antibody-drug
conjugate trastuzumab-emtansine, in patients with human epithelial growth
factor-2 (HER2)-positive breast cancer. Future studies would benefit from a standardized
criterion to define positive tumor uptake, possibly supported by quantitative analysis, and
validated by linking imaging data with corresponding clinical outcome. Taken together,
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these results encourage further studies to develop 89Zr-immuno-PET as a predictive
imaging biomarker to guide individualized treatment, as well as for potential application
in drug development.
Keywords: molecular imaging, positron emission tomography, 89zirconium, monoclonal antibodies, imaging
biomarker, clinical oncology
INTRODUCTION
In recent years, monoclonal antibodies (mAbs) have become
widely used for treatment of cancer. Immunotherapy with mAbs
aims for specific targeting and therefore less toxicity compared
to chemotherapy. Some mAbs have resulted in a significant
improvement of survival, for example the anti-CD20 antibody
rituximab for B cell lymphoma (Feugier et al., 2005). However,
not all patients benefit from mAb treatment. Monotherapy with
the anti-epidermal growth factor receptor (EGFR) antibody
cetuximab results in clinical benefit for half of the patients with
advanced colorectal cancer (without relevant gene mutations;
RAS wild type; Peeters et al., 2015).
Improving response rates by quickly selecting the right drug
for the right patient is paramount to reducing unnecessary
toxicity and costs. In order to obtain clinical benefit from
mAb treatment, the target antigen should be expressed
in the tumor and the drug is required to reach and
bind to the target (tumor targeting). Absence of target
expression on normal tissue is important to limit toxicity of
treatment.
Next generation mAbs are aiming for increased potency,
for example antibody-drug conjugates (ADC’s), mAbs capable
of inhibiting immune checkpoints and multi-specific mAbs
recognizing at least two different targets (Sliwkowski and
Mellman, 2013; Evans and Syed, 2014; Reichert, 2016).
The number of novel targeted treatment options increases,
however drug development requires time, efforts and significant
resources. In addition, investigational drugs are evaluated in
large patient cohorts before successful introduction in routine
clinical care.
Molecular imaging with 89Zr-labeled mAbs, also known as
89Zr-immuno-PET, provides a potential imaging biomarker to
evaluate tumor targeting of mAbs. This technique is non-invasive
and provides whole body information on both target expression
and tumor targeting, as opposed to immunohistochemistry on
a single biopsy, which only provides information on target
expression. Prediction of efficacy and toxicity of mAb treatment
by molecular imaging may be used to select individual patients or
Abbreviations: ADC, antibody-drug conjugate; cmAb U36, chimeric monoclonal
antibody U36; EGFR, epidermal growth factor receptor; FDG, 18F-fluoro-deoxy-
glucose; HNSCC, head and neck squamous cell carcinoma; HER2, human
epidermal growth factor receptor 2; HSP90, Heat shock protein 90; mAb,
monoclonal antibody; MSLN, membrane-bound surface glycoprotein mesothelin;
NET, neuroendocrine tumors; NHL, non-Hodgkin lymphoma; PET, positron
emission tomography; p.i., post injection; PSMA, prostate specific membrane
antigen; RIT, radioimmunotherapy; T-DM1, trastuzumab-emtansine; TGF-β,
Transforming growth factor-β; VEGF-A, vascular endothelial growth factor-A;
90Y, yttrium-90; 89Zr, zirconium-89.
patient groups for a treatment, or to select promising candidate
drugs and their dosing schedule (Ciprotti et al., 2015).
89Zr-immuno-PET allows visualization and quantification of
biodistribution and tumor uptake. 89Zr is considered a suitable
radioisotope for this purpose, due to its relatively long half-life
(t½ = 78.4 h), which corresponds with the time a mAb needs to
reach the target. The use of 89Zr as a radiolabel and the coupling
of 89Zr to mAbs, under GoodManufacturing Practice conditions,
have been described previously (Verel et al., 2003; Perk et al.,
2010; Vosjan et al., 2010). Harmonization of quantitative 89Zr-
immuno-PET imaging has also been reported, allowing for broad
scale application, e.g., in a multi-center setting (Makris et al.,
2014).
Before starting clinical 89Zr-immuno-PET trials, the following
conditions are essential to allow appropriate interpretation of
data. Prerequisites are that the radioimmunoconjugate of
interest is stable and has the same binding and biodistribution
characteristics as the unlabeled parental mAb. Imaging
procedures should be standardized and validated in order
to provide reliable quantification. Assuming these requirements
are fulfilled, biodistribution and tumor uptake of a 89Zr-mAb,
defined on PET, can be used as an imaging biomarker for
tumor targeting of the “cold” therapeutic antibody. These basic
technical aspects of 89Zr-immuno-PET have been extensively
discussed in a recent review by van Dongen et al. (2015).
Until now, at least 15 clinical 89Zr-immuno-PET trials have
been reported, see Table 1, providing information on the clinical
performance of 89Zr-immuno-PET. Therefore, evaluation of the
potential and current limitations of this imaging technique seems
timely to enable optimal design of future trials. This review
summarizes the results from initial clinical 89Zr-immuno-PET in
oncology, and technical aspects of trial design are discussed.
89Zr-LABELED ANTI-CD44V6 MAB IN
HEAD AND NECK CANCER
89Zr-immuno-PET is considered to be an attractive imaging
technique for whole body tumor detection, due to the combined
sensitivity of PET and the specificity of the mAb. Assessment of
the mAb biodistribution to confirm specificity is particularly of
interest to qualify the suitability of the mAb for therapy.
Börjesson et al. reported on the first clinical 89Zr-immuno-
PET study ever (Börjesson et al., 2006). In this study,
twenty pre-operative patients with head and neck squamous
cell carcinoma (HNSCC) were included. Immuno-PET with
89Zr-labeled chimeric mAb U36 (cmAb U36) was investigated
in order to improve tumor detection of HNSCC, especially
in lymph nodes, and to assess the targeting potential of the
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TABLE 1 | Summary of clinical studies on 89Zr-immuno-PET in oncology.
Author Year Target mAb Tumor type N
Börjesson 2006 CD44v6 cmAb U36 Head and neck cancer 20
2009
Dijkers 2010 HER2 trastuzumab Breast cancer 14
Rizvi 2012 CD20 ibritumomab-tiuxetan B-cell lymphoma 7
Gaykema 2013 VEGF-A bevacizumab Breast cancer 23
van Zanten 2013 VEGF-A bevacizumab Glioma 3
van Asselt 2014 VEGF-A bevacizumab Neuroendocrine tumors 14
Bahce 2014 VEGF-A bevacizumab Non-small cell lung cancer 7
Pandit-Taskar 2014 PSMA Hu-J591 Prostate cancer 50
2015
Den Hollander 2015 TGF-β fresolimumab Glioma 12
Gaykema 2015 HER2 trastuzumab Breast cancer 10
VEGF-A bevacizumab 6
Gebhart 2015 HER2 trastuzumab Breast cancer 56
Lamberts 2015 MSLN MMOT0530A Pancreatic cancer 11
Ovarian cancer 4
Menke-van der Houven van Oordt 2015 EGFR cetuximab Colorectal cancer 10
Muylle 2015 CD20 rituximab B-cell lymphoma 5
Oosting 2015 VEGF-A bevacizumab Renal cell carcinoma 22
mAb for therapy. cmAb U36 targets the v6 region of CD44
(cluster of differentiation; CD44v6). Homogeneous expression
of CD44v6 has been observed in several malignancies, including
HNSCC, lung, skin, esophagus, and cervix carcinoma. Expression
of CD44v6 has also been reported in normal epithelial tissues,
such as skin, breast, and prostate myoepithelium, and bronchial
epithelium.
Administration of 74 megabecquerel (MBq) 89Zr-mAb U36
(10mg) appeared to be safe, as no adverse reactions were
observed. A human anti-chimeric antibody response was
reported in 2 patients, which was not directed to the chelate,
but to the protein part of the conjugate. 89Zr-immuno-
PET scans were visually scored. All primary tumors were
detected and 89Zr-immuno-PET performed equally to computed
tomography (CT) and magnetic resonance imaging (MRI)
for detection of lymph node metastasis. Although, biopsies
were obtained in this study to confirm tumor localization,
immunohistochemistry for CD44v6 was not performed, as in
literature >96% of HNSCC show CD44v6 expression by at
least 50% of the cells. This study shows that immuno-PET
with 89Zr-cmAb U36 can be used as an imaging modality for
tumor detection. However, traditional imaging techniques as 18F-
fluoro-deoxy-glucose(FDG)-PET (Mak et al., 2011) and sentinel
node procedures for assessment of lymph node status remain
standard of care for tumor detection in HNSCC patients, as the
added value of immuno-PET with 89Zr-cmAb U36 has not been
demonstrated.
In a separate publication, biodistribution, radiation dose
and quantification of 89Zr-labeled cmAb U36 were reported
for the same patient cohort (Börjesson et al., 2009). 89Zr-cmAb
U36 in blood pool, lungs, liver, kidneys and spleen decreased
over time. Increasing uptake of 89Zr-cmAb U36 over time was
seen only at tumor sites and in the thyroid of some patients
(suggesting expression of CD44v6 in thyroid of these patients).
Although expression of CD44v6 in normal epithelial tissue
has been described, no obvious targeting of 89Zr-mAb U36
was observed in the skin. However, Tijink et al. reported a
fatal adverse event due to skin toxicity after treatment with
the ADC bivatuzumab mertansine, a humanized anti-CD44v6
mAb conjugated to a potent maytansine derivate (Tijink et al.,
2006). This toxicity profile, most probably due to expression of
CD44v6 in the skin, was not predicted based on assessment of
biodistribution of 89Zr-cmAbU36 as reported by Börjesson et al.
(2009). Among others, this may be due to detection limitations
of PET, inter-individual differences in target expression,
or differences in biodistribution between the mAb and
the ADC.
A technical aspect of this first 89Zr-immuno-PET study to
be considered is the rationale for the total protein dose of
cmAb U36 administered, since tumor uptake, tumor to non-
tumor ratio’s, as well as tumor visualization might be protein
dose dependent. This protein dose of 10mg was chosen as
previous studies observed that biodistribution was not mAb-dose
dependent within the range of 2–52mg (de Bree et al., 1995;
Colnot et al., 2000; Stroomer et al., 2000).
Finally, good agreement was reported for image-derived
quantification of blood pool radioactivity as well as tumor
uptake of 89Zr-cmAb U36 compared to ex vivo radioactivity
measurements in, respectively, venous blood samples and
biopsies from surgical tumor resection. This is an important
achievement in performance, showing accurate quantification of
89Zr-mAb with PET.
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FIGURE 1 | Dose-dependent biodistribution and clearance of 89Zr-trastuzumab. Radioactivity in the blood pool and intestinal excretion are indicated by
arrows. (A) Trastuzumab-naïve patient, imaging dose = 10mg. (B) Trastuzumab-naïve patient, imaging dose = 50mg. (C) Patient on trastuzumab treatment, imaging
dose = 10mg. Reprinted with permission from Dijkers et al. (2010).
89Zr-LABELED TRASTUZUMAB IN BREAST
CANCER
Treatment with trastuzumab, which targets the human epidermal
growth factor receptor 2 (HER2), has improved the prognosis
for patients with HER2-positive breast cancer (Moja et al., 2012)
and gastric cancer (Gong et al., 2016). HER2 is involved in cell
survival, proliferation, cell maturation, metastasis, angiogenesis
and has anti-apoptotic effects. It is also expressed in other
malignancies, including ovarian and endometrial carcinoma, and
in normal epithelial cells and hematopoietic cells (Leone et al.,
2003). It is known that the extracellular domain of HER2 can
enter the circulation after shedding from the surface of tumor
cells (Tse et al., 2012).
Currently assessment of HER2 status is performed
with immunohistochemistry (IHC) or fluorescent in situ
hybridization on tumor biopsies. Some studies have shown
up to 15% intra-individual heterogeneity in HER2 status
between primary tumors and metastases (Lindstrom et al.,
2012) leading to the recommendation to repeat biopsies to
assess HER2 status during the course of the disease. As some
tumor lesions are inaccessible for biopsies and it is impossible
to biopsy every tumor lesion to assess heterogeneity, there
is a need for a non-invasive technique to assess whole body
HER2 status for diagnosis, staging and to guide individualized
treatment.
89Zr-Trastuzumab-PET for Whole Body
Assessment of HER2 Target Status
Dijkers et al. reported a feasibility study to determine optimal
dosage and time of administration of 89Zr-trastuzumab (37MBq)
to enable PET visualization and quantification of tumor lesions in
14 patients with HER2-positive metastatic breast cancer (Dijkers
et al., 2010).
Trastuzumab naïve patients who received -89Zr-trastuzumab
(10 mg; n = 2), showed relatively high liver uptake and
pronounced intestinal excretion, with low blood pool activity,
indicating rapid clearance. This rapid clearance was most
probably due to complex formation of trastuzumab with
extracellular HER2 domains shed in the plasma. For optimal
imaging, trastuzumab naïve patients required a total dose of
50mg trastuzumab (n = 5). This resulted in less liver uptake,
lower intestinal excretion and increased blood pool activity,
as illustrated by Figures 1A,B. This dose was considered the
optimal dose, as good tumor-to-non-tumor ratio and favorable
biodistribution were observed, although higher doses were not
evaluated due to expected target saturation. Patients already on
trastuzumab treatment received a dose of 10mg trastuzumab. As
these patients (n = 7) showed minimal intestinal excretion and
slow blood clearance, this was considered an adequate dose, see
Figure 1C. This study illustrates a dose-dependent relationship
between imaging dose and biodistribution of 89Zr-trastuzumab.
Best timing for evaluation of tumor uptake of 89Zr-
trastuzumab was 4–5 days post injection (p.i.) while scans
performed at day 6 or 7 p.i. yielded decreased image quality
because of insufficient counting statistics.
89Zr-trastuzumab-PET allowed detection of most of the
known lesions and some that had remained unnoticed with
CT, MRI or bone scans. In 6 of the 12 patients not all known
lesions were detected. Liver lesions were missed in 3 out of 7
patients, possibly due to the high background activity in normal
liver tissue, which is involved in mAb catabolism. Interestingly,
while poor penetration of trastuzumab in the brain was expected,
in 3 patients brain lesions could be visualized. This might be
due to disruption of blood-brain barrier in brain metastasis. A
limitation of this study was the lack of biopsies for confirmation
of the HER2 status of immuno-PET negative lesions.
Tumor lesions showing no uptake of 89Zr-trastuzumab may
be due to suboptimal imaging conditions, as illustrated by a
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FIGURE 2 | Patterns of HER2-PET/CT confronted with FDG-PET/CT, maximum intensity projection. Lesion uptake was considered pertinent when visually
higher than blood pool. (A) Entire tumor load showed pertinent tracer uptake. (B) Dominant part of tumor load showed tracer uptake. (C) Minor part of tumor load
showed tracer uptake. (D) Entire tumor load lacked tracer uptake. Reprinted with permission from Gebhart et al. (2016).
case report of a trastuzumab naïve breast cancer patient (Oude
Munnink et al., 2010). Thirty seven MBq trastuzumab (50
mg) was administered and a PET scan was obtained 2 days
p.i.. 89Zr activity concentration in bloodpool was low, whereas
massive uptake was observed in liver metastases (48% of the
injected dose) as well as intestinal uptake, suggesting intestinal
excretion. Known bone metastases were hardly visible. This
might be the result of an extensive tumor load and/or soluble
HER2, which reduces uptake in other tumor lesions, due to
an insufficient amount of trastuzumab. After administration
of 220mg unlabeled trastuzumab, immediately followed by
10mg 89Zr-trastuzumab, liver uptake was lowered (33% of the
injected dose) and an increase in uptake in the other tumor
lesions, such as bone metastases, was observed. Based on a
theoretical calculation the authors conclude that a dose of 280mg
trastuzumab could only saturate 47% of all HER2 present in
the liver metastases of this patient, indicating a higher dose of
trastuzumab is required to saturate lesions in case of extensive
HER2-positive tumor load. Based on this important observation
that pharmacokinetics and organ distribution can be influenced
by the extent of tumor load, dosing of trastuzumab formetastastic
breast cancer should be reconsidered. An individualized dosing
schedule of trastuzumab based on tumor load, guided by 89Zr-
trastuzumab-PET, instead of patient weight, might improve
efficacy of treatment.
89Zr-Trastuzumab to Assess Response by
Alteration of Antigen Expression
Gaykema et al. evaluated 89Zr-trastuzumab-PET to determine
alteration of HER2 expression after anti-angiogenic treatment
with the novel heat shock protein 90 (HSP90) inhibitor NVP-
AUY922 in 10 patients with HER2-positive breast cancer
(Gaykema et al., 2014). HSP90 inhibition can deplete client
proteins like HER2. This study was performed with 37MBq 89Zr-
trastuzumab (50mg), while NVP-AUY922 was administered i.v.
in a weekly schedule of 70 mg/m2. Change in tumor uptake
of 89Zr-trastuzumab at baseline vs. 3 weeks on treatment was
correlated to change in size on CT after 8 weeks treatment.
This feasibility study suggests that 89Zr-immuno-PET can be
used to monitor alteration of antigen expression and supports
further evaluation of 89Zr-trastuzumab-PET in providing insight
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in treatment response of novel anti-cancer agents like the HSP90
inhibitor NVP-AUY922 in larger studies.
89Zr-Trastuzumab-PET as Predictive
Imaging Biomarker for ADC Treatment
Recently, the ADC trastuzumab-emtansine (T-DM1) was
approved for treatment of patients with progression
of HER2-positive breast cancer, previously treated with
trastuzumab-based therapy. The ZEPHIR study investigated the
use of 89Zr-trastuzumab-PET, combined with early response
assessment with FDG-PET, as a predictive imaging biomarker
for treatment with T-DM1 (Gebhart et al., 2016). In this study
intra- and interpatient heterogeneity in HER2 mapping of
metastatic disease was also explored, see Figure 2. The study
was performed by administration of 37 MBq 89Zr-trastuzumab
(50mg). 89Zr-trastuzumab-PET scans were acquired 4 days p.i.
and visually scored. After 1 cycle of T-DM1 an early metabolic
response was evaluated by FDG-PET. Clinical outcome after
treatment with 3 cycles of T-DM1 was evaluated by CT.
For 55 evaluable patients with HER2-positive metastatic
breast cancer, assessment of 89Zr-trastuzumab uptake resulted in
a positive predictive value of 72% and a negative predictive value
of 88% for prediction of clinical outcome. For early metabolic
response assessment with FDG-PET the positive predictive value
was 96% and the negative predictive value was 83%. Intrapatient
heterogeneity in tumor uptake was observed in 46% of patients,
as illustrated by Figure 2. When combining 89Zr-trastuzumab-
PET with early FDG-PET response after 1 cycle of T-DM1, a
negative predictive value of 100%was obtained for all concordant
patients (with both a negative 89Zr-trastuzumab-PET, as well
as absence of response on early FDG-PET). This strategy of
combiningHER2-PETwith early FDG-PET responsemonitoring
was able to separate patients with a median time to treatment
failure of 2.8 month from patients with a median time to
treatment failure of 15 months.
It is not known why 2/16 patients with a negative 89Zr-
trastuzumab-PET did show response on treatment with T-DM1.
Some possibilities are lack of receptor overexpression, receptor
masking, or an induced response despite low HER2 expression
due to the extreme potency of T-DM1. Another possibility
is that DM1 becomes released in the circulation and exerts
some antitumor activity. Absence of tumor uptake can also be
explained by an insufficient tracer dose due to the extent of tumor
load or the amount of soluble HER2 in these patients.
These results support that pre-treatment imaging of HER2-
targeting is a promising tool to improve the understanding of
tumor heterogeneity in metastatic breast cancer and to select
patients who are deemed not to benefit from T-DM1. This might
avoid toxicity and costs of T-DM1 and improve patient outcome
by switching sooner to a more effective therapy (personalized
medicine). A plausible explanation for the added value of early
FDG-PET is that although target expression of HER2 is a
prerequisite for clinical benefit, even with adequate targeting
intracellular resistance mechanisms may be responsible for
treatment failure. The authors recommend a future randomized
trial with cost-effectiveness as secondary endpoint, to test the
concept of interrupting T-DM1 treatment after 1 cycle in case of
FDG-PET non-responsiveness, which can be expected in 20% of
the patients. As such, this trial paved the road toward improved
individualization of anti-HER2 therapy.
89Zr-LABELED BEVACIZUMAB IN BREAST
CANCER, LUNG CANCER, RENAL CELL
CARCINOMA, NEUROENDOCRINE
TUMORS, AND PONTINE GLIOMA
Another target for treatment of breast cancer and many other
tumor types is vascular endothelial growth factor A (VEGF-
A), which is involved in tumor angiogenesis. Overexpression
of VEGF-A has been reported in malignant breast tumors and
ductal carcinoma in situ and has been related to aggressiveness of
the disease. Bevacizumab is a mAb that targets all splice variants
of VEGF-A, both small isoforms which can diffuse freely in the
circulation, as well as larger isoforms which are primarily matrix-
bound. Despite the fact that VEGF-A is not a membrane target
like HER2, it is partly associated with the tumor blood vessels and
to some extent with the extracellular matrix of tumor cells, which
could enable imaging of tumor lesions.
It can be hypothesized that local VEGF-A concentration
reflects whether tumor progression is driven by angiogenesis and
if anti-angiogenic treatment is likely to be effective. Therefore,
89Zr-bevacizumab-PET is of interest for several applications:
biological characterization of tumors, prediction of therapeutic
outcome, and treatment evaluation of VEGF-A targeting drugs.
89Zr-Labeled Bevacizumab in Breast
Cancer
Gaykema et al. performed a study to assess whether VEGF-A can
be visualized by 89Zr-bevacizumab-PET in patients with primary
breast cancer who were scheduled for surgery (Gaykema et al.,
2013). In this study 37 MBq 89Zr-labeled bevacizumab (5mg)
was administered and PET scans were acquired at 4 days p.i.. The
same dose was used in a previous study with 111Indium-labeled
bevacizumab, which visualized all known melanoma lesions
(Nagengast et al., 2011). Tumor uptake of 89Zr-bevacizumab
was observed in 25 of 26 tumors in 23 patients with primary
breast cancer. The false-negative tumor was a 10mm VEGF-A-
positive invasive ductal carcinoma. Besides assessment of tumor
uptake in the primary tumors, uptake of 89Zr-bevacizumab in
lymph node metastasis regions was evaluated. 4 of 10 metastasis-
involved lymph node regions were detected in 9 patients. Zero of
4 axillary regions with lymph node metastases were detected by
89Zr-bevacizumab-PET.
For all available tumors (n = 25) VEGF-A expression
was quantified by enzyme-linked immunosorbent assay.
89Zr-bevacizumab uptake in tumors correlated with the
VEGF-A tumor levels measured. Microvessel density
on immunohistochemistry was not correlated with 89Zr-
bevacizumab uptake. This was the first clinical study showing
a significant correlation between antigen expression and tumor
uptake of the mAb. The fact that VEGF-A is not/hardly expressed
in normal tissue, while the antigen might be well accessible for
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mAbs in tumor tissue, might be favorable factors for finding
such a correlation. This observation opens avenues for the use of
89Zr-bevacizumab-PET for response monitoring in therapeutic
strategies aiming to downregulate VEGF-A.
The effect of the HSP90 inhibitor NVP-AUY922 on alteration
of VEGF-A status was evaluated in the same study discussed
earlier for 89Zr-trastuzumab in breast cancer (Gaykema et al.,
2014). However, 89Zr-bevacizumab-PET was not able to predict
treatment outcome measured by CT in patients with estrogen-
receptor-positive breast cancer (n= 6). Possible explanations are
that most lesions found on 89Zr-bevacizumab PET were bone
lesions and not measurable on CT, and that HIF1a is likely a less
prominent client protein of HSP90 than HER2. Target expression
may be dependent on tumor type, as 89Zr-bevacizumab uptake in
breast tumors was consistently lower than in renal cell cancer.
89Zr-Labeled Bevacizumab in Lung Cancer
Bevacizumab is also used for treatment of non-small cell
lung carcinoma and 89Zr-bevacizumab is a potential predictive
imaging biomarker for this patient group. In a pilot study it
was evaluated whether tumor uptake of 89Zr-bevacizumab could
be visualized and quantified in 7 patients with lung cancer
(Bahce et al., 2014). Moreover, in this study the correlation
between tumor uptake of 89Zr-bevacizumab and response to
a bevacizumab-based treatment regimen was explored. 89Zr-
bevacizumab PET was performed at day 4 and 7 after injection
of 37 MBq 89Zr-labeled bevacizumab (5 mg), one week prior
to start of induction therapy with carboplatin, paclitaxel and
bevacizumab (15 mg/kg), followed by bevacizumab maintenance
upon non-progression after 4 cycles.
All tumor lesions showed visible 89Zr-bevacizumab uptake.
Tumor-to-blood ratios increased from 1.2 ± 0.4 to 2.2 ± 1.2
between day 4 and 7 p.i.. Tumor lesions had an approximately
four times higher 89Zr-bevacizumab uptake compared to non-
tumor background tissues (muscle, healthy lung and fatty tissue).
A positive trend, but no significant correlation, was observed for
tumor uptake and progression-free survival and overall survival
after combined chemo-immunotherapy.
A limitation of this study design is that no distinction
is possible between therapeutic contribution of chemotherapy
and immunotherapy, as this is a combined treatment regimen.
Therefore, further 89Zr-bevacizumab-PET studies are required
to assess VEGF-target status after combination treatment, as a
response predictor for effectiveness of subsequent bevacizumab
maintenance therapy.
As all lesions were visualized with a total protein dose of 5mg
89Zr-bevacizumab, and no targeting of normal tissues became
apparent, there is no indication of an antigen sink for this mAb.
A limitation of the current study was that no extra biopsies were
obtained to confirm VEGF-A tumor expression as driver for
89Zr-bevacizumab uptake and therapeutic response.
89Zr-Labeled Bevacizumab in Renal Cell
Carcinoma
Oosting et al. investigated 89Zr-bevacizumab-PET in patients
with metastatic renal cell carcinoma as an imaging modality for
treatment evaluation of anti-angiogenic drugs (Oosting et al.,
2015).
Patients were randomized between treatment with
bevacizumab (10 mg/kg intravenously every 14 days) combined
with interferon-α (3 million IU, 3 times per week) (n = 11) or
sunitinib (50mg orally, daily for 4 weeks followed by 2 weeks
off treatment) (n = 11), which is a multi-targeted receptor
tyrosine kinase inhibitor. At baseline, and 2 and 6 weeks after
treatment, PET scans were acquired after administration of 37
MBq 89Zr-labeled bevacizumab (5 mg).
Tumor lesions were visualized in all patients (in total 125
lesions), including 35 that had not been detected by CT. 19
lesions were outside the field of view of the CT, including 5
brain lesions in 3 patients (two had known brain metastasis).
Remarkable interpatient and intrapatient heterogeneity in tumor
uptake of 89Zr-bevacizumab was observed. A strong decrease in
tumor uptake of −47.0 % at week 2 was observed for patients on
bevacizumab/interferon-α treatment, with an additional change
of −9.7% at week 6. For patients on sunitinib treatment, a mean
change in tumor uptake of −14.3% at week 2 and a rebound of
+72.6% at week 6 was reported (after 2 drug-free weeks).
Change in tumor uptake of 89Zr-bevacizumab did not
correlate with time to progression. Baseline tumor uptake
of 89Zr-bevacizumab corresponded with longer time to
progression. Although, reduced 89Zr-bevacizumab tumor
uptake after treatment might be caused by saturation due to
treatment with unlabeled bevacizumab, other clinical studies
have suggested that bevacizumab-induced vascular changes do
occur after treatment.
Further studies are required to assess whether baseline tumor
uptake of 89Zr-bevacizumab can be used to predict benefit from
anti-angiogenic treatment. Heterogeneity in tumor uptake of
89Zr-bevacizumab may offer a possibility to differentiate patients
groups based on tumor biology and to guide the choice between
anti-angiogenic and other treatment strategies.
89Zr-Labeled Bevacizumab in
Neuroendocrine Tumors
In another feasibility study with 89Zr-bevacizumab, the effect
of everolimus, a mammalian target of rapamycin inhibitor,
on tumor uptake was investigated in patients with advanced
progressive neuroendocrine tumors (NET) (van Asselt et al.,
2014). As everolimus can reduce VEGF-A production, it
was evaluated whether NET lesions can be visualized by
89Zr-bevacizumab PET and whether tumor uptake of 89Zr-
bevacizumab decreases from baseline to week 2 and 12 during
everolimus therapy (10mg orally once daily). This study was also
performed with 37 MBq 89Zr-labeled bevacizumab (5 mg), with
imaging 4 days p.i.. In 4 of 14 patients no tumor lesions could
be visualized with 89Zr-bevacizumab-PET, in the remaining
patients only 19% of tumor lesions ≥1 cm (63 lesions in total)
known by CT were positive at PET, demonstrating variable 89Zr-
bevacizumab tumor uptake in NET patients. 89Zr-bevacizumab
uptake diminished during everolimus treatment with a mean
of −7% at 2 weeks and −35% at 12 weeks. Change in tumor
uptake correlated with treatment outcome, assessed by CT after
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3 months. There was no correlation between baseline tumor
uptake and change of tumor size as assessed by CT, indicating that
89Zr-bevacizumab-PET was not qualified for response prediction
before therapy.
Interestingly, in 4 of 14 patients no visual uptake was
observed, while no patient had progressive disease after 3 and
6 months of treatment with everolimus. This might indicate
that everolimus exerts also other mechanisms of action than just
reduction of VEGF-A, or reflect that NETs are slow growing
tumors.
89Zr-labeled Bevacizumab in Pontine
Glioma
For brain tumors like diffuse intrinsic pontine glioma in children,
it is not known whether targeted drugs actually can reach the
tumor. Nevertheless, several studies are ongoing to investigate
treatment with bevacizumab for this indication. The first report
ever on molecular imaging in children, was a feasibility study on
the therapeutic potential of bevacizumab and toxic risks, due to
VEGF-A expression in normal organs in children with pontine
glioma (van Zanten et al., 2013). 3 patients, aged 6, 7, and 17 years
received 0.9 MBq/kg (range 18–37 MBq) 89Zr–bevacizumab
(0.1mg/kg). Whole body PET scans were obtained at 1, 72, and
144 h p.i.. Tumor uptake of 89Zr-bevacizumab was observed in 2
of 3 patients, limited to the T1-MRI contrast-enhanced part of the
tumor. These findings suggest that disruption of the blood-brain
barrier, as indicated by MRI contrast, is necessary for effective
tumor targeting by 89Zr-bevacizumab. Uptake in normal organs
was highest in the liver, followed by the kidneys, lungs, and bone
marrow. This study illustrates that also in children 89Zr-immuno-
PET is a feasible procedure, and has potential as a response
and toxicity predictor for treatment with bevacizumab and other
targeted drugs.
89Zr-LABELED FRESOLIMUMAB IN
HIGH-GRADE GLIOMA
As indicated before, mAbs might be prevented from reaching
tumor lesions in the brain by impermeability of the blood-
brain barrier, while tumor targeting is a prerequisite for effective
treatment. An appealing target molecule for treatment of high-
grade glioma is transforming growth factor β (TGF-β), which
functions as a tumor promotor and induces proliferation and
metastasis, while suppressing the immune response. TGF-β and
its receptors are overexpressed in high-grade glioma and can be
targeted with several types of TGF-β inhibitors. Fresolimumab is
a mAb capable of neutralizing all mammalian isoforms of TGF-β
(i.e., 1, 2, and 3) and has been investigated in phase I trials with
patients with melanoma, renal cell carcinoma and in a phase II
trial in patients with mesothelioma.
DenHollander et al. investigated uptake of 89Zr-fresolimumab
in 12 patients with recurrent high-grade glioma and assessed
clinical outcome after fresolimumab treatment (den Hollander
et al., 2015). In this study an imaging dose of 37 MBq 89Zr-
fresolimumab (5 mg) was used before start of treatment (5 mg/kg
i.v. every 3 weeks) and PET scans were obtained for all patients
on day 4 p.i., while 4 patients also received a scan at day 2 p.i..
In all patients uptake of 89Zr-fresolimumab was observed in
brain tumor lesions (n = 16), while in 8 patients not all known
brain tumor lesions were visualized with 89Zr-fresolimumab-
PET (mostly small lesions, <10mm on MRI). The three lesions
larger than 10 mm that were missed by 89Zr-fresolimumab-
PET were suspected to represent radionecrosis instead of viable
tumor tissue (therefore probably lacking TGF-β expression),
based on previous irradiation or disappearance on follow-up
MRI. Tumor-to-blood ratios increased from day 2 to 4 p.i.
in patients who underwent whole body PET scans (n = 4),
which was considered to be suggestive for tumor-specific TGF-
β-driven mAb uptake. All patients showed progressive disease on
fresolimumab treatment, therefore no correlation between tumor
uptake of 89Zr-fresolimumab and clinical response was observed.
Because of absence of clinical benefit the study was closed after
the first 12 patients.
In conclusion, this study showed that 89Zr-fresolimumab
reaches brain tumor lesions. mAb treatment with TGF-β
targeting drugs remains an interesting approach for treatment
of high-grade glioma, especially since targeting of brain tumor
lesions has been observed by 89Zr-fresolimumab-PET. Increase
in tumor to blood ratios suggests specific tumor uptake, although
non-specific antibody uptake due to disruption of the blood-
brain barrier cannot be excluded.
89Zr-LABELED CETUXIMAB IN
COLORECTAL CARCINOMA
Another target antigen of interest is EGFR, which can be targeted
with cetuximab. Binding of cetuximab to EGFR prevents growth
factor binding to the receptor, induces receptor internalization,
and causes inhibition of the receptor tyrosine kinase activity. In
this way cetuximab interferes with cell growth, differentiation
and proliferation, apoptosis and cellular invasiveness. Colorectal
cancer with RAS wild type can be effectively treated with
cetuximab, while it is known that patients with a K-RAS or
N-RAS mutation do not respond to anti-EGFR treatment (van
Cutsem et al., 2011). Only patients with RAS wild type colorectal
cancer are eligible for anti-EGFR treatment. However, even in
this selected patient group efficacy of single agent cetuximab
remains limited, as clinical benefit is observed in only half of
the patients (Peeters et al., 2015). Additional growth activating
mutations or insufficient tumor targeting may affect clinical
efficacy. As EGFR is highly expressed on hepatocytes in normal
liver tissue, this might lead to sequestration of anti-EGFR-mAbs
shortly after administration and interfere with effective tumor
targeting.
Assuming that response to treatment is dependent on uptake
of cetuximab in tumor lesions, only patients in whom tumor
targeting can be confirmed will be susceptible to treatment.
Menke-van der Houven van Oordt et al. performed a feasibility
study in 10 patients with advanced colorectal cancer to
investigate biodistribution and tumor uptake of 89Zr-cetuximab
and evaluated 89Zr-cetuximab as a predictive imaging biomarker
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(Menke-van der Houven van Oordt et al., 2015). While blood
pool, spleen, kidney and lung activity decreased, uptake in the
liver increased during the first 2 days, after which a plateau was
reached. Total radioactivity derived from the whole body PET
images decreased due to gastro-intestinal excretion, while no
excretion via the bladder was observed.
Tumor uptake was visible in 6 of 10 patients, of which 4
had clinical benefit. In a patient with 2 lung lesions, one lesion
could be visualized, while the other could not, possibly indicating
intra-individual heterogeneity of receptor expression or an effect
of tumor size (the lesion not visualized was smaller). Of the
remaining 4 out of 10 patients without tumor uptake, 3 had
progressive disease and 1 had clinical benefit without visible
89Zr-cetuximab uptake. Possibly, the amount of cetuximab that
reached the latter tumor was insufficient for visual detection,
but did induce anti-tumor activity. This example indicates
that for appropriate interpretation of tumor uptake-response
relationships it is of paramount importance that 89Zr-cetuximab
and unlabeled cetuximab show exactly the same biodistribution.
Altogether these results support further investigations in a
larger cohort to assess whether 89Zr-cetuximab can discriminate
between cetuximab responding and non-responding patients.
Currently a follow-up study, including dose escalation for
patients without visible tumor uptake of 89Zr-cetuximab and
assessment of cetuximab concentrations in tumor biopsies,
is ongoing (ClinicalTrials.gov Identifier: NCT02117466). A
limitation of 89Zr-cetuximab-PET reported by the authors is
its inability to detect tumor lesions in the liver. In contrast
to 89Zr-trastuzumab, 89Zr-cetuximab specifically accumulates in
normal liver tissue resulting in spillover when quantifying hepatic
lesions. Important technical aspects to consider are whether
the imaging dose (89Zr-labeled cetuximab) and the therapeutic
dose (unlabeled cetuximab) show similar biodistribution, and if
the degree of similarity can be influenced by the sequence of
administration.
In this study patients were treated with a cold therapeutic dose
of cetuximab (500 mg/m2), within 2 h followed by the infusion
of 37 MBq 89Zr-cetuximab (10 mg). It was assumed that within
this time frame the therapeutic dose and the imaging dose behave
as if injected simultaneously due to slow pharmacokinetics.
Sequential administration was chosen to make radiation safety
precautions during administration of 89Zr-cetuximab easier.
Previous studies with 111In-cetuximab (C225) in patients
with squamous cell lung carcinoma have indicated a dose-
dependent biodistribution, showing liver sequestration of 111In-
cetuximab, which decreased with increasing doses of unlabeled
cetuximab (up to 300 mg), while tumor uptake increased
(Divgi et al., 1991). To get better insight in the dose-
dependent biodistribution of 89Zr-cetuximab, Menke-van der
Houven van Oordt et al. administered a scouting dose of
0.1mg 89Zr-cetuximab before the dose of unlabeled cetuximab
in 3 patients (Menke-van der Houven van Oordt et al.,
2015). Blood samples 2 and 3 h post injection of the scouting
dose revealed that only <10% of the injected dose of 89Zr-
cetuximab was left in the blood circulation. When subsequently
cold cetuximab (500 mg/m2) was administered, 89Zr-cetuximab
reappeared in the blood, indicating that it can be reversibly
extracted, most probably by the liver. On the other hand, the
biological half-life of 89Zr-cetuximab, if administered directly
after the unlabeled dose, was comparable with the half-life as
reported for unlabeled cetuximab. This indicates that upon
such sequential administration 89Zr-cetuximab indeed reflects
the biodistribution of unlabeled cetuximab. Future studies are
required to assess to which extent sequential administration of
imaging and therapeutic doses influences tumor biodistribution
and tumor uptake of 89Zr-cetuximab.
89Zr-LABELED ANTI-PSMA IN PROSTATE
CANCER
Current clinical challenges in imaging of metastatic prostate
cancer include limited sensitivity and specificity to detect early
metastases (especially in bone) and active disease and to monitor
treatment of metastatic prostate cancer. The humanized mAb
huJ591 targets the extracellular domain of prostate-specific
membrane antigen (PSMA), a transmembrane glycoprotein
expressed by both benign and malignant prostate epithelial cells.
Nearly all prostate cancers express PSMA. Upon binding, the
huJ591-PSMA complex becomes rapidly internalized. Binding of
anti-PSMA mAbs to non-prostate tissue, as the liver, duodenal
epithelial (brush border) cells and proximal tubule cells in the
kidney, has been observed, as well as binding to tumor-associated
neovasculature in other solid malignancies, including clear cell
renal carcinoma, colon and breast carcinoma (Chang, 2004).
Recently, Pandit-Taskar et al. performed a clinical study
with 89Zr-labeled huJ591 in 50 patients with castrate-resistant
metastatic prostate cancer (Pandit-Taskar et al., 2015). Results
of the first 10 patients were reported separately, including
assessment of optimal imaging time post-injection for lesion
detection of 89Zr-huJ591 PET imaging (Pandit-Taskar et al.,
2014). These 10 patients received 4 scans within 8 days after
injection. Based on optimal tumor-to-background ratios, the
other 40 patients were imaged once at 6–8 days p.i.. In this
89Zr-immuno-PET study a total mAb dose of 25mg huJ591 was
used, of which 1.7mg was 89Zr-labeled (203 MBq). This dose
was based on prior studies with 111In-J591 and 177Lu-J591 that
showed saturation of PSMA expressed by the normal liver at
25mg of huJ591 (Morris et al., 2005). A dose-dependent uptake
in the liver with increasing mAb dose was observed, and optimal
trade off was reached at a mAb dose of 25mg. The unlabeled
dose of huJ591 was administered intravenously within 5 min,
immediately followed by injection of 89Zr-huJ591 within 1 min.
Pandit-Taskar et al. evaluated performance characteristics of
89Zr-DFO-huJ591 PET/CT for detecting metastases compared
to conventional imaging modalities (baseline FDG-PET, 99mTc-
methylenediphosphonate (MDP) bone scans and CT scans) and
pathology, to provide evidence for the use of 89Zr-huJ591 as an
imaging biomarker. In a lesion-based analysis 89Zr-J591 imaging
demonstrated superior visualization of bone lesions relative to
conventional imaging, see Figure 3. However, detection of soft
tissue lesions was suboptimal. A generalized lower tumor uptake
was observed for soft tissue lesions compared to bone lesions.
Low uptake was observed in normal bone and considered to be
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FIGURE 3 | 89Zr-huJ591-PET and conventional imaging modalities of a patient with rising prostate specific antigen. 99mTc-MDP bone scan shows only a
few lesions. FDG-PET shows nodal disease in the thorax, retroperitoneum, and pelvic region and a few bone lesions in the spine. Overall more bone lesions were seen
on 89Zr-huJ591-PET than on FDG-PET, including multiple lesions in vertebrae, pelvic bones, ribs, and humerus. Targeting was also seen to the retroperitoneal and
pelvic lymph nodes by 89Zr-huJ59-PET. (A) Anterior and posterior 99mTc-MDP bone scan. (B) FDG-PET maximum intensity projection. (C)89Zr-huJ591 PET. (D)
FDG-PET sagittal fused image. (E) 89Zr-hu J591 PET sagittal fused image. Reprinted with permission from Pandit-Taskar et al. (2014).
non-specific. Among the possibilities explaining a lower tumor
uptake in soft tissue are: lower PSMA expression, absence of
tumor in lesions presumed to be disease by CT and FDG-PET
scan, or impaired accessibility of PSMA for intact mAbs. For
the biopsy-confirmed lesions overall accuracy of 89Zr-J591 was
95.2% (20/21) for osseous lesions and 60% (15/25) for soft-tissue
lesions. No data is provided on 89Zr-J591 uptake related to PSMA
expression in tumor biopsies.
The authors conclude that 89Zr-huJ591 imaging is able
to detect active disease earlier than conventional imaging,
making PSMA an attractive target for diagnosis of prostate
cancer. Despite the fact that just a small proportion of
lesions were biopsied, statistical arguments indicated that
89Zr-huJ591 imaging detects 50% more bone lesions (occult
disease) than bone scan. However, no single imaging modality
can serve as gold standard, therefore a known site of
disease was defined as any lesions identified by conventional
imaging at baseline. Small lesions were most probably missed,
while the treatment of patients after imaging was variable,
which limits the detection of lesions through follow-up
imaging.
The relatively long period post injection required for optimal
imaging, may be a practical limitation of 89Zr-immuno-PET for
routine application in diagnosis. Promising alternative ligands
for molecular imaging of prostate cancer are smaller molecules as
radiolabeled minibodies or urea-based small peptides, although
none have been validated in controlled clinical trials for routine
clinical use (Viola-Villegas et al., 2014). The perspectives of 89Zr-
immuno-PET might be different when considering 89Zr-huJ591
for therapeutic approaches.
89Zr-LABELED ANTI-MSLN IN
PANCREATIC AND OVARIAN CARCINOMA
For several tumor types, such as pancreatic and ovarian
carcinoma, no important drug targets are available. Exploitation
of tumor-specific membrane proteins, even those without a
known role in oncogenesis, as targets for delivery of potent drugs
by ADCs is a promising approach. In this respect, a potential
target molecule, with largely unknown biological function, is
membrane-bound surface glycoprotein mesothelin (MSLN). It is
minimally expressed by normal mesothelial cells, lining pleural,
pericardial and peritoneal surfaces. Besides in mesothelioma,
it is also highly overexpressed in 80-100% of pancreatic and
ovarian cancers (and some other cancers). In preclinical studies
with MSLN-expressing tumor bearing mice, 89Zr-anti-MSLN
antibody MMOT0530A showed progressive and antigen-specific
tumor uptake with micro-PET (Ter Weele et al., 2015).
Therefore, Lamberts et al. evaluated 89Zr-labeled
MMOT0530A as a predictive imaging biomarker for treatment
(in a phase I setting) with the ADC DMOT4039A, containing
the MSLN-antibody MMOT0530A combined with the cytotoxic
agent monomethyl auristatin E (Lamberts et al., 2016). For such
an approach either the ADC itself can be labeled with 89Zr or
the corresponding “naked” mAb, if available for human use.
Labeling of the mAb part of the ADCs with 89Zr is well possible,
but requires advanced analytical tools to prove that labeling
is performed inertly. Assuming that both types of conjugates
demonstrate similar biodistribution, which is a research question
as such, PET imaging of the target will provide insight into
drug distribution (tissue exposure, but also expression of the
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target and internalization of the antibody). Ideally, clinical
89Zr-immuno-PET studies with the “naked” mAb are performed
before resources are put in the development of an ADC.
The aim of this imaging study was to assess biodistribution
and tumor uptake, and the relationship between tumor uptake
and MSLN expression, as well as response to treatment. Uptake
in normal tissues was as expected, and did not indicate specific
uptake, except for high hepatic uptake of 89Zr-MMOT0530A.
This might be due to normal hepatic catabolism of the antibody,
maybe slightly elevated by complex formation of the mAb
with MSLN antigen shed into the circulation, as MSLN is not
expressed on normal liver. Nevertheless, the uptake level in liver
was similar to that of other antibodies such as trastuzumab and
huJ591. Significant clinical toxicity, reported as dose limiting
toxicity, were hypophosphatemia and hyperglycaemia and liver
function abnormalities occurred in less than 10% of these
patients. Tumor uptake of 89Zr-MMOT0530Awas observed in 37
tumor lesions in 11 patients with pancreatic cancer and 4 patients
with ovarian cancer, while 6 measurable tumor lesions visible on
diagnostic CT in 4 patients were not detected by 89Zr-immuno-
PET. Within patients a mean 2.4 ± 1.1-fold difference in uptake
between tumor lesions was observed, indicating interlesional
heterogeneity of tumor uptake.
Tumor uptake of 89Zr-MMOT0530A was correlated with
MSLN expression levels determined with IHC scores (6 patients
with pancreatic cancer and 4 patients with ovarian cancer).
No correlation was found when the two tumor types were
analyzed separately. Tumor uptake of 89Zr-MMOT0530A was
not correlated with progression free survival, on both patient and
lesion-based analysis.
The imaging dose for this study was considered to be
sufficient, since the amount of tracer still present at 7 days p.i.
was enough to clearly visualize the circulation. A first cohort
of two patients received 37 MBq 89Zr-anti-MSLN (1 mg) and
were imaged at days 2, 4 and 7 p.i.. Patients in the second
cohort (n = 10) received a total protein dose of 10mg mAb,
administered as a co-infusion. The biological half-life of 89Zr-
anti-MSLN in cohort 1 was shorter than in cohort 2, most likely
due to faster antibody clearance related to small amounts of shed
MSLN antigen present in the circulation. Bioavailability of the
imaging dose in the second cohort was considered sufficient to
evaluate tumor uptake.
This was the first study aiming the use of 89Zr-immuno-
PET as an imaging biomarker for whole body target expression
and organs at risk for toxicity, to ultimately guide dosing,
confirm delivery, and predict efficacy of the ADC. At this
stage of development, however, 89Zr-immuno-PET was not able
yet to add valuable information for individualized treatment
decisions.
89Zr-LABELED ANTI-CD20 MABS IN B
CELL LYMPHOMA
Especially when using mAbs for radioimmunotherapy (RIT),
89Zr-immuno-PET may be applied to predict toxicity by
assessment of biodistribution. This information may enable
individualized treatment by optimizing dose schedules to limit
unnecessary toxicity for patients.
RIT is used in the treatment of lymphoma, as this type
of cancer is highly radiosensitive. More than 90% of B-
cell non-Hodgkin lymphoma (NHL) express CD20, making
it an attractive target for treatment. The transmembrane
phosphoprotein CD20 is also expressed on mature B cells. The
biological function of CD20 is still unclear. CD20 is highly
expressed on the cell surface and is not rapidly internalized after
antibody binding. The anti-CD20 antibody rituximab is widely
used in both first-line, as well as subsequent treatment lines for
patients with B-cell NHL. Anti-CD20 based RIT with yttrium-
90 (90Y)-labeled-ibritumomab tiuxetan is currently approved for
treatment of relapsed and refractory NHL (Mondello et al., 2016).
Bone marrow toxicity of RIT is dose-limiting, and especially
patients with bone marrow infiltration may suffer excessive
hematotoxicity.
Rizvi et al. published a clinical study on 89Zr-immuno-
PET to predict toxicity of RIT in NHL patients in order to
guide individualized dose optimization (Rizvi et al., 2012).
The aim of this study was to assess whether pre-therapy
scout scans with 89Zr-ibritumomab tiuxetan can be used to
predict biodistribution of 90Y-ibritumomab tiuxetan and the
dose limiting organ during therapy. Patients received standard
treatment of 250 mg/m2 rituximab 1 week before and on the
same day prior to both 90Y-and/or 89Zr-ibritumomab tiuxetan
(70 MBq) administrations. The correlation between predicted
pre-therapy and therapy organ absorbed doses as based on
89Zr-ibritumomab tiuxetan images was high. Biodistribution of
89Zr-ibritumomab tiuxetan was not influenced by simultaneous
therapy with 90Y-ibritumomab tiuxetan. Pre-therapy scout scans
with 89Zr-ibritumomab tiuxetan can therefore be used to
predict biodistribution and dose-limiting organ during therapy.
These results indicate that 89Zr-immuno-PET may guide safe
individualized therapy by optimizing the radioimmunotherapy
dose of 90Y-ibritumomab tiuxetan.
The standard treatment with a high amount of cold rituximab
before anti-CD20 based RIT, also administered to the patients
in the study of Rizvi et al., is common practice to enhance the
therapeutic index for RIT. It is thought that the usage of excess
unlabeled mAb before RIT may reduce toxicity, in particular
bone marrow toxicity. Preloading with unlabeled mAb might
prevent normal tissue toxicity by providing a more predictable
biodistribution of 90Y-labeled mAb, decreasing clearance rates,
and prolonging its circulation half-life. This preload is assumed
to clear the peripheral blood of circulating CD20-positive B
cells and enhance tumor targeting of the 90Y-labeled antibody
to tumor cells. However, supportive data for this approach is
limited. It is unclear whether the preload may block subsequently
administered 90Y-labeled anti-CD20 antibody, which might
impair therapeutic effects.
Muylle et al. performed a study with 89Zr-rituximab-PET to
explore the influence of a preload with unlabeled rituximab in
five patients with CD20-positive B-cell lymphoma, scheduled for
subsequent RIT with 90Y-labeled rituximab (Muylle et al., 2015).
The aim of the study was to compare the distribution of 89Zr-
rituximab without and with a preload of unlabeled rituximab
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FIGURE 4 | 89Zr-rituximab-PET images obtained 6 days after injection. (A) Patient 2 without B cell depletion, anterior view. (B) Patient 3 with B cell depletion,
posterior view. Reprinted with permission from Muylle et al. (2015).
(within the same patient) to assess the impact on tumor targeting
and radiation dose of subsequent radioimmunotherapy with 90Y-
labeled rituximab. PET scans were obtained at baseline after
administration of 111MBq 89Zr-labeled rituximab (10mg). After
3 weeks, a standard preload of unlabeled rituximab (250 mg/m2)
was administered, immediately followed by administration of
10mg 89Zr-rituximab, and PET scans were acquired.
For the patients with B cell depletion (n = 3) tumor uptake
without a preload was consistently higher. In patients with
preserved circulating B cells (n = 2), 3 lesions showed less or
no uptake without a preload, while other lesions showed higher
uptake. The authors explain higher tumor uptake upon preload
by improved biodistribution and prevention of sequestration of
89Zr-rituximab in the “antigen-sink,” consisting of CD20-positive
B cells in the circulation and in the spleen. Impaired targeting of
other tumor sites, however, is explained by partial saturation with
unlabeled rituximab.
For patients with preserved circulating CD20-positive B-cells
(n = 2) without a preload of unlabeled rituximab, an increase in
whole-body radiation dose of 59 and 87% was observed mainly
due to increased uptake in the spleen, see Figure 4. The effective
dose of 89Zr-rituximab was 0.50 milliSievert (mSv)/MBq without
a preload and 0.41 mSv/MBq with a preload.
These results suggest that administration of the standard
preload of unlabeled rituximab impairs tumor targeting of 89Zr-
rituximab in patients with B-cell depletion, due to previous
treatment with rituximab. These data suggest that common
practice of preloading with unlabeled rituximab before RIT
should be re-evaluated and reconsidered.
CONCLUSIONS AND FUTURE
DIRECTIONS
In clinical trials with 89Zr-immuno-PET, two requirements
should be met in order to realize its full potential. One
requirement is that the biodistribution of the 89Zr-mAb (imaging
dose) should reflect the biodistribution of the drug during
treatment (therapeutic dose). An important pitfall to eliminate
is a “false negative” 89Zr-immuno-PET due to absence of tumor
uptake of the imaging dose, while there is tumor targeting of
the therapeutic dose of unlabeled mAb. This situation may occur
in case of expression of target antigen on normal tissue, or
in case of a large tumor load with antigen expression. This
causes an “antigen sink” that absorbs the tracer dose, leaving
insufficient 89Zr-mAb to target all tumor lesions. Therefore, for
each mAb, information should be obtained to assess whether
a dose-dependent correlation between imaging dose and tumor
uptake exists. Preferably a pilot study with different dose levels,
within the same patient, is used to define the optimal 89Zr-
mAb dose for imaging, i.e., the dose that reflects the therapeutic
dose best. With respect to this, in case of co-administration of
89Zr-labeled and cold mAb, it should also be confirmed whether
simultaneous administration is needed, or whether sequential
administration immediate after each other is allowed.
Another requirement is that tumor uptake of the 89Zr-mAb
reflects specific, antigen-mediated, tumor targeting. Next to
specific uptake, also non-antigen mediated tumor uptake can
occur, possibly caused by enhanced permeability and retention
in tumor tissue. Even when tracer uptake is visualized in the
tumor, no biological effect can be expected if tumor uptake is
not primarily antigen-mediated (a “false positive” 89Zr-immuno-
PET). Two clinical studies have reported a correlation between
tumor uptake on PET and target expression in biopsies (Gaykema
et al., 2013; Lamberts et al., 2016) indicating that tumor
uptake on 89Zr-immuno-PET reflects specific, antigen-mediated
binding. This would allow the use of 89Zr-immuno-PET as an
imaging biomarker to assess target expression, as well as tumor
targeting. However, for every mAb-antigen combination this has
to be confirmed. In order to evaluate to which extent tumor
uptake is driven by nonspecific and/or specific binding, studies
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correlating tumor uptake to target expression in biopsies, as well
as exploration of kinetic modeling, may provide further insight.
Assuming these two crucial requirements are met, 89Zr-
immuno-PET can be expected to predict toxicity and response
to treatment.
For RIT, it was shown that biodistribution of 89Zr-rituximab
can be used to predict biodistribution and the dose-limiting
organ for subsequent treatment with 90Y-ibritumomab tiuxetan
(Rizvi et al., 2012). This allows for future application of 89Zr-
immuno-PET for individualized doze optimization of RIT with
the aim to reduce the risk for toxicity. However, so far no clinical
studies reported that 89Zr-immuno-PET predicted toxicity of
mAb or mAb conjugate treatment.
Prediction of response to treatment for mAbs, is based on
the assumption that the drug can only be effective if the target
antigen is reached. Although, this is no guarantee for efficacy,
as therapy failure may occur due to inadequate dosing of the
mAb or intrinsic resistance mechanisms. On the other hand
efficacy might occur at low antigen expression levels which is
not visualized by 89Zr-immuno-PET. To improve prediction
of efficacy of treatment, confirmation of tumor targeting of
the drug can be combined with early response assessment.
This combined approach may be able to predict whether
adequate tumor targeting is followed by sufficient cytotoxicity.
Clinical application of molecular imaging to guide individualized
treatment may ideally consist of the following 3-step approach:
1. Tumor detection and staging of the disease with conventional
imaging (e.g., FDG-PET/diagnostic CT)
2. Assessment of tumor targeting of the drug with molecular
imaging (e.g., 89Zr-immuno-PET)
3. Early response assessment on treatment with conventional
imaging (e.g., FDG-PET/diagnostic CT)
So far, the ZEPHIR study is the only study utilizing this 3-step
approach, using an optimized 89Zr-mAb dose for imaging, and
a visual classification for tumor uptake (Gebhart et al., 2016).
This study reported that molecular imaging combined with early
response assessment is able to predict response to treatment
with T-DM1 in patients with HER2-positive breast cancer,
opening avenues to cost-effectiveness studies and individualized
treatment protocols. Still, this promising result can possibly
benefit from improving criteria of positive uptake by quantitative
analysis.
Currently, no standardized scale for visual scoring of 89Zr-
immuno-PET is available, as opposed to scoring FDG-PET/CT
scans by the Deauville criteria (Meignan et al., 2010). Imaging
procedures, including data analysis and measurements of tumor
uptake should be standardized and validated in order to use
89Zr-immuno-PET in clinical practice. As an example, problems
with partial volume effects should be solved. Ideally, by linking
imaging data with corresponding clinical outcome of a large set
of patients, a criterion for positive tumor uptake can be defined.
Overall, these initial clinical trials have provided indications
of the potential of 89Zr-immuno-PET as an imaging biomarker
to assess target expression, as well as tumor targeting. The
first results supporting application of molecular imaging for
prediction of toxicity for RIT and response prediction for
treatment with an ADC, form an important first step toward
individualized treatment.
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